(NASDAQ: AKBA) Akebia Therapeutics's forecast annual revenue growth rate of 19.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 80.59%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.89%.
Akebia Therapeutics's revenue in 2025 is $184,909,000.On average, 4 Wall Street analysts forecast AKBA's revenue for 2025 to be $54,399,760,711, with the lowest AKBA revenue forecast at $50,636,189,181, and the highest AKBA revenue forecast at $61,278,193,256. On average, 4 Wall Street analysts forecast AKBA's revenue for 2026 to be $75,381,737,649, with the lowest AKBA revenue forecast at $56,965,712,828, and the highest AKBA revenue forecast at $104,082,581,807.
In 2027, AKBA is forecast to generate $80,954,082,181 in revenue, with the lowest revenue forecast at $70,517,721,966 and the highest revenue forecast at $88,757,780,776.